OBJECTIVE: Apart from its role in bone metabolism, vitamin D may also influence cardiovascular disease. The objective of this study was: (1) to determine the effect of a single, oral, high-dose vitamin D supplementation on endothelial function and arterial stiffness in patients with peripheral arterial disease (PAD) and (2) to investigate the impact of this supplementation on coagulation and inflammation parameters. METHODS: In this double-blind, placebo-controlled, interventional pilot study, we screened 76 Caucasian patients with PAD for vitamin D deficiency. Sixty-two were randomised to receive a single, oral supplementation of 100,000 IU vitamin D3 or placebo. At baseline and after 1 month, we measured serum vitamin D and parathormone levels, and surrogate parameters for cardiovascular disease. RESULTS:Sixty-five of 76 patients (86%) had low 25-hydroxyvitamin D levels (<30 ng ml(-1)); of those, 62 agreed to participate in the study. At baseline, only parathormone was related to vitamin D. In supplemented patients, vitamin D levels increased from 16.3 ± 6.7 to 24.3 ± 6.2 ng ml(-1) (P < 0.001), with wide variations between single patients; in the placebo group vitamin levels did not change. Seasonal factors accounted for a decrease of vitamin D levels by 8 ng ml(-1) between summer and winter. After 1 month, none of the measured parameters was influenced by vitamin substitution. CONCLUSION: In this pilot study, most patients with PAD were vitamin D deficient. Vitamin D supplementation increased serum 25-hydroxyvitamin D without influencing endothelial function, arterial stiffness, coagulation and inflammation parameters, although the study was underpowered for definite conclusions.
RCT Entities:
OBJECTIVE: Apart from its role in bone metabolism, vitamin D may also influence cardiovascular disease. The objective of this study was: (1) to determine the effect of a single, oral, high-dose vitamin D supplementation on endothelial function and arterial stiffness in patients with peripheral arterial disease (PAD) and (2) to investigate the impact of this supplementation on coagulation and inflammation parameters. METHODS: In this double-blind, placebo-controlled, interventional pilot study, we screened 76 Caucasian patients with PAD for vitamin D deficiency. Sixty-two were randomised to receive a single, oral supplementation of 100,000 IU vitamin D3 or placebo. At baseline and after 1 month, we measured serum vitamin D and parathormone levels, and surrogate parameters for cardiovascular disease. RESULTS: Sixty-five of 76 patients (86%) had low 25-hydroxyvitamin D levels (<30 ng ml(-1)); of those, 62 agreed to participate in the study. At baseline, only parathormone was related to vitamin D. In supplemented patients, vitamin D levels increased from 16.3 ± 6.7 to 24.3 ± 6.2 ng ml(-1) (P < 0.001), with wide variations between single patients; in the placebo group vitamin levels did not change. Seasonal factors accounted for a decrease of vitamin D levels by 8 ng ml(-1) between summer and winter. After 1 month, none of the measured parameters was influenced by vitamin substitution. CONCLUSION: In this pilot study, most patients with PAD were vitamin D deficient. Vitamin D supplementation increased serum 25-hydroxyvitamin D without influencing endothelial function, arterial stiffness, coagulation and inflammation parameters, although the study was underpowered for definite conclusions.
Authors: C Custodero; R T Mankowski; S A Lee; Z Chen; S Wu; T M Manini; J Hincapie Echeverri; C Sabbà; D P Beavers; J A Cauley; M A Espeland; R A Fielding; S B Kritchevsky; C K Liu; M M McDermott; M E Miller; R P Tracy; A B Newman; W T Ambrosius; M Pahor; S D Anton Journal: Ageing Res Rev Date: 2018-05-25 Impact factor: 10.895
Authors: Olena Andrukhova; Svetlana Slavic; Ute Zeitz; Sabine C Riesen; Monika S Heppelmann; Tamas D Ambrisko; Mato Markovic; Wolfgang M Kuebler; Reinhold G Erben Journal: Mol Endocrinol Date: 2013-01-01
Authors: Marc Blondon; Mary Cushman; Nancy Jenny; Erin D Michos; Nicholas L Smith; Bryan Kestenbaum; Ian H de Boer Journal: J Clin Endocrinol Metab Date: 2016-03-29 Impact factor: 5.958
Authors: Rebecca Hodge; Hannah B Mandle; Stephen Ray; Sonia Tandon; Meaghan Peterson; Abigail Henry; Ferdous A Jahan; Roberd M Bostick; John A Baron; Elizabeth L Barry; Rami Yacoub; Robin E Rutherford; March E Seabrook; Veronika Fedirko Journal: Cancer Prev Res (Phila) Date: 2018-09-12
Authors: Louise A Beveridge; Allan D Struthers; Faisel Khan; Rolf Jorde; Robert Scragg; Helen M Macdonald; Jessica A Alvarez; Rebecca S Boxer; Andrea Dalbeni; Adam D Gepner; Nicole M Isbel; Thomas Larsen; Jitender Nagpal; William G Petchey; Hans Stricker; Franziska Strobel; Vin Tangpricha; Laura Toxqui; M Pilar Vaquero; Louise Wamberg; Armin Zittermann; Miles D Witham Journal: JAMA Intern Med Date: 2015-05 Impact factor: 21.873
Authors: Azizah Mat Hussin; Ammar W Ashor; Inez Schoenmakers; Tom Hill; John C Mathers; Mario Siervo Journal: Eur J Nutr Date: 2016-02-05 Impact factor: 5.614